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ABSTRACT 
Vitamin E is a highly effective fat-soluble vitamin with a variety of cellular membrane stabilizing-antioxidant 
and non-antioxidant functions. Vitamin E has been suggested to prevent the oxidation of polyunsaturated fatty 
acids in red blood cell (RBC) membrane, thus inhibiting the premature erythrocytelysis.   Animal studies have 
shown that treatment with vitamin E results in increased number of colony forming units of erythroid 
precursors, enhanced erythropoiesis and improved blood hemoglobin levels in these animals. Several clinical 
trials have indicated that vitamin E might be used therapeutically as a potential erythropoietic agent for 
decreasing the premature erythrocyte hemolysis by reducing the fragility of erythrocytes.  By this way, it improves 
the post-supplemental blood hemoglobin and hematocrit levels in some of the anemic human subjects, including 
low birth weight premature infants, patients suffering from various types of inherited hemolytic anemia, chronic 
renal failure patients on hemodialysis and apparently healthy mildly anemic subjects. 
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INTRODUCTION 
 
Anemia is a major public health problem worldwide, 
especially in the developing countries. The highest 
prevalence of anemia is seen in Africa, but the largest 
numbers of the anemic individuals are found in countries 
of South-East Asia, where approximately 315 million 
individuals have been estimated to be suffering from 
anemia (Benoist et al., 2008). 
 
The causes of anemia are diverse and multifactorial, 
however, leading etiologies in the developing countries 
are: nutritional deficiencies, malabsorption, chronic or 
acute blood loss, inherited genetic defects, chronic 
diseases, parasitic infestations, premature hemolysis of 
RBCs, decreased medullary erythropoiesis or an 
undefined cause (Antonio et al., 2009). 
 
Anemia is a not a disease, but rather a sign of an 
underlying illness.  Therefore, management of anemia 
should focus on identification and removal of the 
underlying cause. Many of the hematinic micronutrients, 
including iron, folate, vitamin B12, vitamin B6, vitamin A, 
vitamin C and vitamin E have been used in the past for 
treatment and/or prevention of various types of anemia, 
with variable hematological responses to these 
interventions (Fishman et al., 2000). 
 
Vitamin E- a highly potent antioxidant                                                                                                                                        
Oxidative stress corresponds to an imbalance between the 
production of reactive oxygen species (ROS) and the 
protective capacity of antioxidative enzymes and vitamins, 
including vitamins A, C and E. Vitamin E was originally 
considered a dietary factor of animal nutrition, especially 
important for their normal reproduction. The significance of 
vitamin E has been subsequently proven as an essentially 
required cellular component that can protect the integrity of 
cellular membranes and play an important role in various 
biological processes. 
 
Vitamin E is an effective lipophilic vitamin, whose major 
role is to act as a highly potent antioxidant against the 
damaging ROS and peroxyl free radicals, which are 
produced as a result of cellular oxidative stress. The main 
dietary sources of vitamin E include vegetable seeds and 
their oils, nuts, almonds, fish, some cereals and some of the 
green leafy vegetables. The term vitamin E refers to eight 
essential naturally occurring isomeric forms that possess a 
similar chemical structure comprising a chromanol ring with 
a 16-carbon side chain. The isomeric forms with saturated 
side chain are called “tocopherols”, while isomeric forms 
with unsaturated side chain are termed as “tocotrienols” 
(Muller et al., 2010). 
 
The most abundant and biologically active isoform of 
vitamin E in the human body is alpha-tocopherol (Engin, 
2009). Alpha-tocopherol has the maximum bioavailability 
among all the forms and is selectively recognized and 
transported inside the cells with the help of a cytosolic 
liver protein, termed as α-tocopherol transfer protein 
(Christopher Min, 2007). The most well-known function 
of vitamin E is to terminate a radical-propagated chain of 
lipid peroxidation reaction. Vitamin E protects the 
polyunsaturated fatty acids (PUFAs) of the cellular *Corresponding author: e-mail: tanveer.jilani@aku.edu
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membranes and low-density lipoproteins (LDL) from 
oxidative damage by free radicals. In this manner, vitamin 
E serves to protect and stabilize the cellular membranes 
through its role as a powerful antioxidant (Brigelius-
Flohe, 2009).  
 
Non-antioxidant functions of vitamin E                                                                                                                                         
Molecules in biological systems often perform more than 
one function. In particular, many molecules have the ability 
to chemically scavenge free radicals, but they may also act 
as hormones, ligands for transcription factors, modulators of 
enzymatic activities or as structural components. During the 
last two decades, the potential impact of vitamin E on 
health and various life processes has been intensely 
studied and debated.  More recently, vitamin E has been 
found to possess functions that are independent of its 
well-defined cellular membrane stabilizing and free-
radical scavenging ability (Banks et al., 2010).  
 
Vitamin E has been suggested to regulate enzyme 
activities, signal transduction and gene expression (Sen et 
al., 2007). It has previously been reported in the literature 
that the activity of the enzymes such as protein kinase C, 
tyrosine kinase, 5-lipoxygenase, 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase and 
phospholipase A2 is significantly reduced, while that of 
diacylglycerol kinase and protein phosphatase 2A is 
increased in the presence of α-tocopherol (Upadhyay and 
Misra, 2009). Vitamin E has been shown to modulate the 
activity of both inflammatory cytokines and immune cells 
(Huey et al., 2008). Vitamin E has also been reported to 
inhibit smooth muscle cell proliferation (Zou et al., 2007). 
Epidemiological and experimental studies have suggested 
that antioxidants like vitamin E may play an important 
role in the prevention of certain chronic diseases. Large 
scale clinical trials have been carried out to find out the 
effect of vitamin E supplementation in the prevention of 
ischemic heart disease, cancers and neurodegenerative 
diseases (Lee et al., 2005; Dong et al., 2009; Muller, 
2010). However, the results of these clinical studies have 
been inconclusive, and the expected benefits of vitamin E 
supplementation in the prevention of some of the chronic 
diseases need to be clearly shown (Clarke et al., 2008; 
Brigelious-Flohe and Galli, 2010).  
 
Therapeutic uses of vitamin E in prevention and/or 
treatment of anemia                         
While iron deficiency is regarded as the major cause of 
nutritional anemia, insufficient levels of vitamins B12, A, 
C, E, folate and riboflavin have also been found to be 
associated with it. Therapeutic use of antioxidant vitamins 
has gained considerable interest during the last decade 
(Rodrigo et al., 2007). Some of the earlier animal and 
human studies showed that vitamin E might be having an 
important role in the prevention of oxidation of PUFAs in 
RBC membrane, thereby maintaining red cell membrane 
integrity and inhibiting oxidative stress-induced 
premature erythrocyte lysis (Elaroussi et al., 2007).  
 
Vitamin E has been identified as an essential 
erythropoietic factor for certain species of animals (Chou 
et al., 1978; Fitch et al., 1980). Previous studies have 
shown that treatment with vitamin E increased the number 
of colony forming units of erythroid precursors (CFU-E), 
enhanced erythropoiesis and hemoglobin levels and, thus 
corrected the experimentally-induced anemia in 
laboratory animals (Gogu et al., 1991; Bartholomew et 
al., 1998; Cherdyntseva et al., 2005). However, vitamin E 
has not been reported to be normally required for 
erythropoiesis in healthy humans (Drake and Fitch, 1980).  
Results of some of the clinical trials suggested that 
vitamin E might be having a role as a potential 
erythropoietic agent in some of the anemic human 
subjects, including low birth weight infants, patients 
suffering from various types of inherited hemolytic 
anemia, chronic renal failure patients on hemodialysis and 
mildly anemic apparently healthy subjects. 
 
1. Results of vitamin E supplementation in premature 
infants 
Studies have shown that premature infants are born with 
low serum levels of vitamin E, which may predispose 
them to enhanced RBC hemolysis by free radicals, 
including the hydrogen peroxide (Melhorn et al., 1971).  
Treatment of low birth weight infants with routine 
pharmacological doses of vitamin E has been suggested to 
control hemolytic anemia, thereby correcting hemoglobin 
concentration and preventing the development of 
retinopathy of prematurity and chronic lung disease in 
these preterm babies (Brion et al., 2003).  
In a recent study, it was demonstrated that when iron 
supplementation was given along with dl-alpha 
tocopherol to 2-3 weeks old preterm neonates, it resulted 
in significantly increased post-supplemental blood 
hemoglobin levels along with a decreased reticulocyte 
count in comparison to the basal levels in these neonates 
(Arnon et al., 2009). 
 
2. Clinical trials of vitamin E in patients with some types 
of the inherited hemolytic anemia  
The normal RBC is remarkably pliable, flexible and non-
rigid, that is capable of changing its shape as it circulates in 
the blood stream. Hemolytic anemia is characterized by an 
abnormal premature RBC lysis, shortened RBC survival 
time and increased reticulocytosis. Sickle cell anemia, 
thalassemia, and glucose-6-phosphate dehydrogenase 
deficiency are all hereditary disorders with greater 
vulnerability of RBCs to oxidative damage, often 
resulting in clinical manifestation of mild to severe 
hemolysis in patients with these disorders. Deficiency of 
vitamin E is a common feature in many of the hereditary 
types of hemolytic anemia.  Supplementation of vitamin E 
may have an important role in maintaining red cell 
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membrane integrity by reducing fragility of erythrocytes and 
therefore could minimize the severity of some types of the 
hemolytic anemia. Therapeutic trials had been conducted to 
determine the role of vitamin E for the prevention and /or 
treatment for some types of hemolytic anemia. 
 
a. Role of Vitamin E in patients suffering from sickle cell 
anemia 
Sickle cell disease is characterized by formation of a 
qualitatively abnormal type of hemoglobin, Hb S. Hb S is 
formed as a result of genetic mutation which causes the 
substitution of valine for glutamine at the sixth codon of 
the β-globin chain of adult type of hemoglobin (HbA). 
With deoxygenation, the Hb S molecule becomes 
insoluble and polymerizes, so that the intracellular portion 
of the RBC becomes more viscous. The RBCs then 
become less flexible, rigid and acquire a sickle shape 
during passage through the microcirculation. Sickle cell 
anemia is characterized by increased oxidative stress, 
which makes the sickle erythrocytes more susceptible to 
peroxidation in comparison to the normal erythrocytes 
(Ren et al., 2008).  
                               
This increased susceptibility to peroxidation had been 
proposed, in part, due to decreased blood levels of 
antioxidant vitamins and to an abnormal membrane 
phospholipid organization induced by sickling. The 
peroxidative damage of sickled erythrocytes may 
accelerate loss of cell deformability and a shortened RBC 
survival (Hasanato, 2006).  Decreased plasma levels of 
vitamin E have been found in patients suffering from 
sickle cell disease compared to age and body mass index 
(BMI)-matched healthy controls. Supplementation with 
alpha-tocopherol in children suffering from sickle cell 
anemia has been shown to significantly reduce the 
percentage of irreversibly sickled red cells, increased 
resistance of RBCs to lysis, increased hematocrit and 
enhanced blood hemoglobin concentration (Jaja et al., 
2005).  
 
b. Role of Vitamin E supplementation in thalassemia 
patients 
Thalassemia refers to a group of genetically inherited 
quantitative hemoglobin disorders, characterized by 
reduced synthesis of either α or β-globin polypeptide 
hemoglobin chain and a subsequent imbalance in α/β-
globin chain ratio.  The relative excess of the remaining 
non-defective β or α -globin subunit becomes 
accumulated and precipitated within the red cell 
precursors, resulting in ineffective erythropoiesis, damage 
to erythroid precursor membrane and lysis of mature 
erythrocytes leading to hemolytic anemia. The 
manifestations of thalassemia range from mild anemia 
with microcytosis (thalassemia minor/ β-thalassemia trait) 
to fatal severe anemia (β- thalassemia major). Patients of 
beta thalassemia major, especially who had a history of 
multiple blood transfusions, are at a risk of iron overload 
and enhanced oxidative stress, which may reduce the 
RBC life span (Athanassios et al., 2007).  Some of the 
studies carried out on thalassemia patients have reported 
significantly low blood levels of antioxidant vitamins 
including vitamin E in comparison with healthy control 
subjects (Chiou et al., 2006). In order to minimize the 
oxidative damage to erythrocytes and erythroid precursor 
cells in thalassemia, intervention trials with antioxidant 
vitamins, alone or in combination, have been performed.  
 
Some of these trials have shown that supplementation 
with alpha-tocopherol in patients suffering from 
homozygous ß-thalassemia was effective in reducing 
plasma levels of lipid peroxidation end products and a 
significant improvement in the post-supplemental 
hemoglobin levels (Das et al., 2004). A 4-8 weeks 
supplementation with vitamin E given to children with 
various types of thalassemia had been shown to 
significantly decrease hydrogen peroxide-mediated red 
cell hemolysis and increase the RBC resistance to 
oxidative damage (Suthutvoravut, 1993).  
 
c. Role of vitamin E in patients suffering from glucose-6-
phosphate-dehydrogenase (G6PD) deficiency  
G6PD is a key enzyme in hexose monophosphate 
pathway, which generates reductive energy in RBC in the 
form of reduced nicotinamide adenine dinucleotide 
phosphate (NADPH). NADPH maintains glutathione in 
the reduced state when erythrocytes are subjected to an 
oxidative stress. G6PD deficiency is the most common 
genetic metabolic enzyme defect in human biology.   
Most common clinical manifestations of G6PD-deficient 
subjects include neonatal jaundice and chronic hemolytic 
anemia.  In this condition less deformable RBCs are 
unable to prevent the oxidation of hemoglobin and the red 
cell membrane. Deficiency of antioxidant vitamins is a 
common feature in some patients suffering from G6PD 
deficiency.  An acute hemolytic crisis may occur in these 
patients under certain conditions, such as ingestion of 
fava beans, certain drugs and severe infections (Abdul-
Razzak et al., 2008).  
 
Some of the previous reports have indicated decreased 
blood levels of vitamin E in G6PD deficient patients 
compared to healthy controls.   After 16-week of vitamin 
E therapy there was significant improvement in blood 
hemoglobin levels along with decreased reticulocytosis 
and percentage of hemolysed RBCs in these patients 
(Eldamhougy et al., 1988).  
 
A recent study showed that patients with G6PD 
deficiency had significantly increased osmotic fragility of 
erythrocytes compared to healthy controls. After vitamin 
E supplementation in these patients for 60 days, fragility 
of erythrocytes significantly decreased, while the blood 
hemoglobin levels and red cell indices improved towards 
normal (Sultana et al., 2009). 
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3. Vitamin E in the treatment of chronic renal failure 
patients  
Chronic renal failure is characterized by reduced 
erythropoietin production by the kidney and severe 
uremia, which may lead to bone marrow suppression, 
ineffective erythropoiesis, shortened erythrocyte survival 
and renal anemia. The end-stage renal failure patients 
usually require long term hemodialysis and renal 
transplantation. Thus, the need for exogenous 
erythropoietic factors, including specific hematinic agents 
is increased in the end-stage renal failure patients. 
 
Recent reports emphasize the role of reactive oxygen 
species and/or decreased activity of antioxidant systems 
in chronic renal failure patients, especially those on 
dialysis (Zwolinska et al., 2009).  
 
Several studies have suggested beneficial effects of both 
oral vitamin E supplementation and vitamin E-coated 
dialyzer in reducing the hemodialysis-mediated oxidative 
stress in chronic kidney disease patients (Mydlik et al., 
2006). During the last decade, recombinant human 
erythropoietin (rHuEPO) has been used along with some 
of the antioxidants for treatment of anemia and oxidative 
stress in these chronic renal failure patients on 
hemodialysis. As a result of these clinical trials, it has 
been shown that a combination of rHuEPO and vitamin E 
therapy for the treatment of renal anemia in chronic renal 
failure patients on hemodialysis would significantly 
decrease RBC fragility and increase the post-
supplemental hemoglobin and hematocrit levels (Nemeth 
et al., 2000; Cruz et al., 2008).  
 
4. Vitamin E in the treatment of apparently healthy 
subjects with borderline anemia  
In a preliminary study, vitamin E supplementation given 
for a period of 3 months was found to increase the blood 
hemoglobin levels in mildly anemic adults, with basal 
borderline levels of hemoglobin (11.6-13.5 g/dl in males 
and 9.0-10.9 g/dl in females) (Jilani et al., 2008).  It was a 
small study on 30 subjects with mild anemia, however, if 
the findings of this study could be replicated using a large 
sample size, it might pave way for a simple and 
inexpensive way of treating such anemia.    
 
Mechanism of vitamin E in the treatment and/ or 
prevention of anemia                                        
No definitive mechanism has been reported so far.  
However, vitamin E might be playing a role in the 
treatment of anemia by: 
a.  Inhibiting the oxidation of PUFAs in RBC 
membrane, thus reducing the fragility of erythrocytes 
and preventing the oxidative stress-induced 
premature erythrocyte lysis during various types of 
hemolytic anemia. 
b. Enhancing erythropoiesis in experimental animals 
and some of the anemic human subjects, thereby, 
improving blood hemoglobin and hematocrit levels in 
these individuals.  
 
CONCLUSION                                                                                     
 
Recent reports have shown that vitamin E has multiple 
non-antioxidant functions along with its well-established 
basic cellular antioxidant function. Vitamin E has the 
potential to be affectively used for preventing/and or 
treating some types of the human anemia due to its 
putative role in promoting erythropoiesis, enhancing the 
integrity and stability of erythrocyte membrane proteins 
and lipids, and reducing the oxidative stress-induced 
erythrocyte fragility and lysis. This results in increasing 
RBC survival and improves blood hemoglobin levels.  
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